Call us at:
Equipped with state-of-the-art facilities and experienced immunology experts, Creative Biolabs has expanded its service capabilities to offer a fully integrated CAR-T Cell Display Platform. This new platform will accelerate the timeline for cell and gene therapy development to best suit your program requirements.
Chimeric antigen receptor (CAR) T cell therapies have achieved considerable progress in clinical cancer immunotherapy. However, safety challenges remain. A major problem is the response that CARs to an antigen present on healthy cells (on-target, off-tumour response). One effective strategy to improve this situation is to design the affinity of CARs so that they are activated only by tumor cells expressing high antigen levels.
Over years, Creative Biolabs has established a unique CAR T cell display platform that enables the engineering of variants based on antigen binding and/or signaling-based screening. By using the CRISPR-Cas9 genome editing system, we have generated an antigen-binding domain variants library with different binding affinity. Through several rounds of functional screening and deep sequencing guided selection, CAR variants selectively activated by tumor cells were distinguished based on antigen expression level. What is more, the green fluorescence reporter (GFP) reporter gene can be integrated downstream of the endogenous interleukin-2 (IL-2) gene to facilitate high-throughput screening of activated T cells by fluorescence-activated cell sorting (FACS).
Creative Biolabs' scientists are dedicated to bringing together years of valuable experience to help our clients shorten the clinical study journey. We are committed to providing CAR-T display platform to reduce the overall project development timeline for our clients. For further details, please don't hesitate to contact us and see how we can help you reach your clinical vision.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
Angiotensin-converting Enzyme 2 (ACE2)-CHO Cell Line Model for COVID-19: Helps researchers to further study the interaction between the receptor ACE2 and the COVID-19 virus.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE